Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study

Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study

Background Squamous non-small cell lung cancer (sq-NSCLC) remains a major cause of cancer-related mortality in world. While immunotherapy combined with chemotherapy has improved outcomes, response rates and survival remain suboptimal. Anti-angiogenic agents, such as recombinant human vascular endoth...

Full description

Saved in:
Bibliographic Details
Main Authors: Junzhu Xu MS, Mi Meng MS, Sisi He PhD, Shixiang Wang PhD, Jie Peng PhD, Biao Yao MS, Yi Li MS, Yong Hu MS, Xiaobin Qian BS, Tianwu Wang BS, Hu Ma PhD, Jian-guo Zhou PhD
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/15330338251345913
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/15330338251345913

Similar Items